ログイン
ランキング
お知らせ
ログイン
文献詳細
セミナー 泌尿器科医に必要なPET検査の知識―有用性と問題点・2
文献概要
要約 PETによる核医学画像診断の有用性は，用いるPET薬剤の種類や性能に大きく依存している。今日，泌尿器科領域では主に代謝機能を画像化するPET薬剤によって，悪性腫瘍の検出や病期診断が行われている。今後，受容体や癌抗原などの分子標的を特異的に検出する新規PET薬剤が開発されることにより，診断精度の向上や治療モニタリングなどへの応用などが期待される。
参考文献
1）Hara T, Kosaka N and Kishi H：PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 39：990-995, 1998
2）Narayanan TK, Said S, Mukherjee J, et al：A comparative study on the uptake and incorporation of radiolabeled methionine, choline and fluorodeoxyglucose in human astrocytoma. Mol Imaging Biol 4：147-156, 2002
3）Yoshimoto M, Waki A, Obata A, et al：Radiolabeled choline as a proliferation marker：comparison with radiolabeled acetate. Nucl Med Biol 31：859-865, 2004
C］choline does not correlate with cell proliferation in human prostate cancer. Eur J Nucl Med Mol Imaging 32：668-673, 2005
F-labeled choline analogs as oncologic PET tracers. J Nucl Med 42：1805-1814, 2001
F］fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse：experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 33：1387-1398, 2006
7）Shreve P, Chiao PC, Humes HD, et al：Carbon-11-acetate PET imaging in renal disease. J Nucl Med 36：1595-1601, 1995
8）Yoshimoto M, Waki A, Yonekura Y, et al：Characterization of acetate metabolism in tumor cells in relation to cell proliferation：acetate metabolism in tumor cells. Nucl Med Biol 28：117-122, 2001
. Brain Res 380：336-340, 1986
C NMR. J Biol Chem 265：12916-12926, 1990
C-acetate. J Nucl Med 48：420-428, 2007
12）Kubota K, Ito M, Fukuda H, et al：Cancer diagnosis with positron computed tomography and carbon-11-labelled L-methionine. Lancet 19：1192, 1983
C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med 43：46-55, 2002
protein synthesis rates with PET. J Nucl Med 29：1419-1427, 1988
? J Nucl Med 34：1936-1943, 1993
F-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer. J Nucl Med 48：46-55, 2007
F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med 48：56-63, 2007
with［F-18］FLT and positron emission tomography. Nat Med 4：1334-1336, 1998
F］FLT-PET in oncology：current status and opportunities. Eur J Nucl Med Mol Imaging 31：1659-1672, 2004
20）Oyama N, Ponde DE, Dence C, et al：Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation. J Nucl Med 45：519-525, 2004
21）Dehdashti F, Picus J, Michalski JM, et al：Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging 32：344-350, 2005
F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med 45：366-373, 2004
23）Anastasi A, Erspamer V and Bucci M：Isolation and structure of bombesin and alytesin, 2 analogous active peptides from the skin of the European amphibians Bombina and Alytes. Experientia 27：166-167, 1971
］bombesin in the frog Bombina orientalis. J Biol Chem 271：7731-7737, 1996
）bombesin by tumor cells. Prostate 25：29-38, 1994
26）Markwalder R and Reubi JC：Gastrin-releasing peptide receptors in the human prostate：relation to neoplastic transformation. Cancer Res 59：1152-1159, 1999
］bombesin in human prostate adenocarcinoma xenografts. J Nucl Med 45：1390-1397, 2004
Cu bombesin analogs：side-by-side comparison of the CB-TE2A and DOTA chelation systems. J Nucl Med 48：1327-1337, 2007
F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J Nucl Med 47：492-501, 2006
F-labeled BBN-RGD heterodimer for prostate cancer imaging. J Nucl Med 49：453-461, 2008
31）Manyak MJ, Javitt M, Kang PS, et al：The evolution of imaging in advanced prostate cancer. Urol Clin North Am 33：133-146, 2006
32）Yao D, Trabulsi EJ, Kostakoglu L, et al：The utility of monoclonal antibodies in the imaging of prostate cancer. Semin Urol Oncol 20：211-218, 2004
imaging in experimental models of prostate cancer. Clin Cancer Res 11：4022-4028, 2005
F］DCFBC：a new imaging probe for prostate cancer. Clin Cancer Res 14：3036-3043, 2008
掲載誌情報
